Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
Status:
Active, not recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This research is being done to assess the effectiveness and safety of the combination of
nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory
multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Andrew Yee, MD
Collaborators:
Bristol-Myers Squibb Takeda Pharmaceuticals North America, Inc.